Japan Drug Registration Requirements: What Foreign Companies Need to Know

Japan's Regulatory Framework: MHLW, PMDA, and PAL

Understanding Japan's drug registration requirements starts with understanding the three pillars of its regulatory system.

The Ministry of Health, Labour and Welfare (MHLW) is the top-level government body responsible for pharmaceutical policy in Japan. MHLW grants final marketing approval for all drugs, medical devices, and regenerative medicine products. However, MHLW delegates the heavy lifting of scientific review to its technical arm.

The Pharmaceuticals and Medical Devices Agency (PMDA) is the agency that actually reviews your application. PMDA conducts scientific evaluations of quality, efficacy, and safety data. It also handles pre-submission consultations, GMP inspections, and post-marketing safety monitoring. Think of PMDA as Japan's equivalent of the FDA's review divisions — but with some significant procedural differences that catch foreign companies off guard.

The Pharmaceutical Affairs Law (PAL), now formally known as the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, is the legal foundation governing all pharmaceutical activities in Japan. It defines who can manufacture, import, distribute, and sell pharmaceutical products. PAL was substantially revised in 2005 and again in 2014, introducing the current Marketing Authorization Holder system that every foreign company must understand.

How They Work Together

The typical flow is: PMDA reviews your application and issues a review report with recommendations. The Pharmaceutical Affairs and Food Sanitation Council (PAFSC), an advisory body to MHLW, reviews PMDA's recommendation. MHLW then issues the final approval. In practice, PMDA's recommendation is almost always followed — so your real hurdle is convincing PMDA's reviewers.

Marketing Authorization Holder (MAH) Requirement

This is the single most important requirement that foreign companies must address first: you cannot hold a marketing authorization in Japan unless you have a legal entity in Japan.

Under PAL, the Marketing Authorization Holder (MAH) must be a corporation registered in Japan. The MAH bears full legal responsibility for the product — quality, safety, efficacy, and post-market vigilance. This is non-negotiable. There is no mechanism for a foreign company headquartered outside Japan to directly hold a Japanese marketing authorization.

Foreign companies typically handle this in one of three ways:

• Establish a Japanese subsidiary — The most common approach for large pharma companies. Your KK (Kabushiki Kaisha) or GK (Godo Kaisha) becomes the MAH. This gives you full control but requires significant investment in local personnel, including qualified persons (General Marketing Compliance Officer, Quality Assurance Supervisor, and Safety Management Supervisor).
• Partner with a Japanese pharmaceutical company — A co-development or licensing agreement where the Japanese partner serves as MAH. Common for mid-size companies entering Japan for the first time. The trade-off is reduced control over commercialization.
• Use a contract MAH service — A growing niche where specialized firms serve as your MAH in Japan. This is faster to set up than a subsidiary but requires careful contractual arrangements to ensure alignment on regulatory and commercial decisions.

Regardless of which route you choose, the MAH must have three qualified persons on staff in Japan: a General Marketing Compliance Officer, a Quality Assurance Supervisor, and a Safety Management Supervisor. These roles have specific licensing and experience requirements under PAL.

Required Documents for Registration

Japan's drug registration requirements for documentation follow the ICH Common Technical Document (CTD) format, but with Japan-specific additions. As of April 2026, submissions must use eCTD v4.0 formatfor electronic filing through PMDA's gateway system.

CTD Module Structure for Japan

• Module 1 (Regional Administrative Information) — Japan-specific forms, application forms (in Japanese), and certificates. This module is entirely Japan-specific and differs significantly from US or EU Module 1 content.
• Module 2 (Summaries) — Quality Overall Summary, Nonclinical Overview and Summaries, Clinical Overview and Summaries. Key sections must be submitted in Japanese.
• Module 3 (Quality) — Drug substance and drug product quality data. Largely follows ICH guidelines, but PMDA may request additional stability data under Japanese storage conditions.
• Module 4 (Nonclinical) — Pharmacology, pharmacokinetics, and toxicology study reports. PMDA expects full study reports, not just summaries.
• Module 5 (Clinical) — Clinical study reports, including any Japan-specific bridging or confirmatory studies.

Japanese Translation Requirements

Not everything needs to be in Japanese, but critical documents do. The application form, Module 1 administrative documents, and key summaries in Module 2 (CTD Summaries and Overviews) must be in Japanese. Individual clinical study reports in Module 5 can be submitted in English, but PMDA reviewers may request Japanese translations of specific sections during the review process. Budget for translation costs and timelines — regulatory Japanese translation is a specialized skill and quality matters enormously.

Clinical Data Requirements

Japan's approach to clinical data is shaped by the concept of ethnic sensitivity — the recognition that drug response can differ across ethnic populations due to genetic, physiological, and cultural factors. ICH E5 provides the framework, but PMDA applies it with particular rigor.

Bridging Studies

If your drug was developed primarily with data from non-Japanese populations, PMDA will typically require a bridging study— a clinical study conducted in Japanese patients designed to "bridge" the foreign clinical data to the Japanese population. The goal is to demonstrate that the foreign data are applicable to Japanese patients.

A bridging study usually involves pharmacokinetic comparisons, dose-response evaluation, and sometimes efficacy/safety endpoints in Japanese subjects. The size and scope vary by drug class and the degree of expected ethnic sensitivity. For drugs with high ethnic sensitivity (e.g., drugs metabolized by polymorphic enzymes like CYP2C19, which has higher prevalence of poor metabolizers in Japanese populations), PMDA may require a full confirmatory clinical trial in Japan.

Multi-Regional Clinical Trials (MRCTs)

The preferred modern approach is to include Japanese sites in your global pivotal trials from the start. Under ICH E17 guidelines, multi-regional clinical trials that include an adequate Japanese subpopulation can often eliminate the need for separate bridging studies. PMDA has been increasingly encouraging this approach, and it can significantly shorten your path to approval in Japan.

Japan-Specific Dose Considerations

Japanese patients frequently require lower doses than Western patients for the same therapeutic effect. This is well-documented across multiple drug classes. PMDA reviewers will scrutinize your dosing rationale carefully. If your global dose was determined primarily in non-Asian populations, expect detailed questions about dose appropriateness for Japanese patients.

GMP Compliance and Inspections

All manufacturing sites producing drug substance or drug product for the Japanese market must comply with Japanese GMP standards. While broadly aligned with ICH Q7 (for APIs) and PIC/S GMP standards, Japan has specific requirements that go beyond what companies may be accustomed to in the US or EU.

• Pre-approval GMP inspection — PMDA conducts a GMP compliance inspection as part of the approval process. This applies to both domestic and overseas manufacturing sites. Foreign site inspections are conducted by PMDA inspectors traveling to your facility.
• MF (Master File) system — Japan uses a Master File system where drug substance manufacturers can register proprietary manufacturing and quality information directly with PMDA, allowing MAH applicants to reference it without accessing confidential details.
• Periodic GMP inspections — After approval, GMP compliance is re-inspected every 5 years as part of the marketing authorization renewal process.
• Change management — Post-approval manufacturing changes follow a tiered notification system. Significant changes require prior approval (partial change application), while minor changes may require only notification.

Foreign manufacturing sites should prepare for PMDA inspections well in advance. Inspectors will review documentation, manufacturing records, and quality systems. Having Japanese-speaking quality staff or qualified interpreters is strongly recommended — inspection findings and corrective actions will be communicated in Japanese.

Pricing and Reimbursement: The NHI System

Getting your drug approved by PMDA is only half the battle. In Japan, pricing and reimbursement are directly linked. Japan operates a universal health insurance system, and virtually all approved prescription drugs are listed on the National Health Insurance (NHI) Drug Price List.

How NHI Drug Pricing Works

Unlike the US, where manufacturers can set their own prices, Japan's drug prices are determined by the government through a formulaic process. The primary pricing method for new drugs is cost-comparison (類似薬効比較方式) — your drug is compared to the most similar existing drug on the NHI list, and priced relative to it.

If no comparable drug exists, cost-accounting (原価計算方式) is used, which builds up the price from manufacturing costs, R&D costs, distribution costs, and an operating margin. Premium adjustments can be added for innovation, utility, marketability, or pediatric formulations.

Price Revisions

Japan revises NHI drug prices annually (shifted from biennial to annual in 2021). Prices generally go down over time through market expansion re-pricing, re-pricing based on actual market prices, and other adjustment mechanisms. Companies must factor this price erosion into their Japan market financial models.

Timing Matters

NHI listing typically occurs within 60-90 days after MHLW approval. However, the pricing negotiation with MHLW's pricing committee can take time. Strategic companies begin informal pricing discussions during the review process to minimize the gap between approval and reimbursement.

Orphan Drug and SAKIGAKE Incentives

Japan offers several incentive programs that can significantly accelerate and de-risk your registration pathway.

Orphan Drug Designation

Japan's orphan drug program provides substantial benefits for drugs targeting diseases with fewer than 50,000 patients in Japan:

• Priority review by PMDA (shorter review timelines)
• Extended re-examination period (up to 10 years of data exclusivity)
• Tax credits for R&D expenses (up to 12%)
• Subsidies for clinical trial costs
• Priority consultation slots at PMDA

SAKIGAKE Designation

The SAKIGAKE (先駆け) designation system, introduced in 2015 and formalized into law in 2019, provides an accelerated pathway for innovative drugs that address serious conditions with high unmet medical need. Key benefits include:

• Prioritized pre-submission consultation with dedicated PMDA reviewers
• Substantial reduction in review time (target of 6 months versus the standard 12 months)
• Extended re-examination period
• Close PMDA engagement during development — PMDA assigns a dedicated review team during the clinical development phase

The catch: SAKIGAKE designation requires that Japan be included in early clinical development and that the drug be filed in Japan simultaneously with or ahead of other markets. It is designed to incentivize "Japan first" development strategies.

Conditional Early Approval

For drugs targeting serious diseases with no alternative treatments, Japan allows conditional early approval based on limited clinical data. The MAH must conduct post-marketing studies to confirm efficacy and safety. This pathway has been used for several oncology and rare disease treatments.

Common Mistakes Foreign Companies Make

After working with regulatory intelligence data from hundreds of PMDA submissions, certain patterns emerge in how foreign companies stumble during Japan drug registration.

1. Starting the MAH setup too late — Establishing a Japanese entity, hiring qualified persons, and obtaining the necessary licenses takes 6-12 months minimum. Companies that wait until late-stage development to address this lose significant time.
2. Underestimating PMDA pre-consultation importance— PMDA offers formal pre-submission consultations (対面助言) that are far more structured and influential than FDA pre-IND or pre-NDA meetings. Skipping these or treating them casually is a critical error. PMDA's feedback in these sessions often directly shapes approval outcomes.
3. Ignoring ethnic sensitivity data requirements — Assuming that global clinical data alone will be sufficient for Japan without any bridging data. PMDA takes ICH E5 seriously. Plan for bridging studies or include Japanese sites in your global trials from Day 1.
4. Inadequate Japanese language capabilities — Regulatory interactions with PMDA are conducted primarily in Japanese. Submission summaries must be in Japanese. Review questions arrive in Japanese. Companies without strong bilingual regulatory staff struggle with response quality and timelines.
5. Not engaging with pricing early enough — The NHI pricing process has its own timeline and complexities. Companies that treat pricing as an afterthought often face delays between approval and commercial launch, or end up with suboptimal pricing.
6. Overlooking GMP inspection preparation — PMDA GMP inspections of foreign manufacturing sites require careful advance preparation. Deficiencies found during inspection can delay approval by months.
7. Failing to research PMDA precedent — PMDA publishes review reports for all approved drugs, containing detailed reasoning on clinical data requirements, risk-benefit assessments, and approval conditions. Not studying relevant review reports for similar drugs is like going to court without reading case law.

Timeline: Pre-Consultation to Market Launch

A realistic Japan drug registration timeline for a new molecular entity, assuming clinical development is already underway globally:

Total time from first PMDA interaction to commercial launch: approximately 3-6 years, depending on whether Japan-specific clinical work is needed. Companies that include Japanese sites in global trials from the start can compress this significantly.

How PharmaLens Can Help

Navigating Japan drug registration requirements demands deep understanding of PMDA's expectations, precedent decisions, and current regulatory trends. The best source of this intelligence is PMDA's own review reports — but most are only available in Japanese.

PharmaLensprovides structured, English-language access to PMDA's drug approval data, covering 1,400+ approved drugs with daily updates. Use it to research how PMDA has evaluated similar drugs, what clinical data requirements were applied, what approval conditions were imposed, and how review timelines compared across therapeutic areas.

Whether you're planning your Japan market entry strategy, preparing for a PMDA pre-consultation, or benchmarking your drug against approved competitors, PharmaLens gives you the regulatory intelligence you need — without requiring Japanese language skills.

References

• PMDA: Review Services for New Drugs
• PMDA: GMP / QMS / GCTP Inspections
• MHLW: Pharmaceutical Policy
• ICH E5: Ethnic Factors in the Acceptability of Foreign Clinical Data
• ICH E17: Multi-Regional Clinical Trials

Source: PMDA Website, MHLW Website. This article is for informational purposes only and does not constitute regulatory advice.